

MD7005/MD7255 - Advanced Injectable Therapies

Advanced Injectable Therapies

View Online



Ajikumar B Aryangat, & John E Gerich. (2010). Type 2 diabetes: postprandial hyperglycemia and increased cardiovascular risk. *Vascular Health and Risk Management*, 6. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2860446/>

Anderson, B., Funnell, M., & American Diabetes Association. (2005). *The art of empowerment: stories and strategies for diabetes educators* (2nd ed). American Diabetes Association.

Ashwell, S. G., Amiel, S. A., Bilous, R. W., Dashora, U., Heller, S. R., Hepburn, D. A., Shutler, S. D., Stephens, J. W., & Home, P. D. (2006). Improved glycaemic control with insulin glargine plus insulin lispro: a multicentre, randomized, cross-over trial in people with Type 1 diabetes. *Diabetic Medicine*, 23(3), 285–292. <https://doi.org/10.1111/j.1464-5491.2005.01781.x>

Bergenstal, R. M., Tamborlane, W. V., Ahmann, A., Buse, J. B., Dailey, G., Davis, S. N., Joyce, C., Peoples, T., Perkins, B. A., Welsh, J. B., Willi, S. M., & Wood, M. A. (2010). Effectiveness of Sensor-Augmented Insulin-Pump Therapy in Type 1 Diabetes. *New England Journal of Medicine*, 363(4), 311–320. <https://doi.org/10.1056/NEJMoa1002853>

Bolinder, J., Antuna, R., Geelhoed-Duijvestijn, P., Kröger, J., & Weitgasser, R. (2016). Novel glucose-sensing technology and hypoglycaemia in type 1 diabetes: a multicentre, non-masked, randomised controlled trial. *The Lancet*, 388(10057), 2254–2263. [https://doi.org/10.1016/S0140-6736\(16\)31535-5](https://doi.org/10.1016/S0140-6736(16)31535-5)

Bretzel, R. G., Nuber, U., Landgraf, W., Owens, D. R., Bradley, C., & Linn, T. (2008). Once-daily basal insulin glargine versus thrice-daily prandial insulin lispro in people with type 2 diabetes on oral hypoglycaemic agents (APOLLO): an open randomised controlled trial. *The Lancet*, 371(9618), 1073–1084. [https://doi.org/10.1016/S0140-6736\(08\)60485-7](https://doi.org/10.1016/S0140-6736(08)60485-7)

Buse, J. B., Bergenstal, R. M., Glass, L. C., Heilmann, C. R., Lewis, M. S., Kwan, A. Y. M., Hoogwerf, B. J., & Rosenstock, J. (2011). Use of Twice-Daily Exenatide in Basal Insulin-Treated Patients With Type 2 Diabetes. *Annals of Internal Medicine*, 154(2). <https://doi.org/10.7326/0003-4819-154-2-201101180-00300>

Carver, C. (2006). Insulin Treatment and the Problem of Weight Gain in Type 2 Diabetes. *The Diabetes Educator*, 32(6), 910–917. <https://doi.org/10.1177/0145721706294259>

Crasto, W., Jarvis, J., Hackett, E., Nayyar, V., McNally, P. G., Davies, M. J., & Lawrence, I. G. (2009). Insulin U-500 in severe insulin resistance in type 2 diabetes mellitus. *Postgraduate Medical Journal*, 85(1002), 219–222. <https://doi.org/10.1136/pgmj.2008.073379>

- Daly, H., Davies, M., Barnett, J., Amin, S., Gray, G., Leonard, J., Northern, A., Crasto, W., Khunti, K., & Jarvis, J. (2015). Development of a self-management education module for those with type 2 diabetes on injectable therapies. *Practical Diabetes*, 32(8), 305–310a. <https://doi.org/10.1002/pdi.1979>
- Davies, M. J., Donnelly, R., Barnett, A. H., Jones, S., Nicolay, C., & Kilcoyne, A. (2009a). Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. *Diabetes, Obesity and Metabolism*, 11(12), 1153–1162. <https://doi.org/10.1111/j.1463-1326.2009.01154.x>
- Davies, M. J., Donnelly, R., Barnett, A. H., Jones, S., Nicolay, C., & Kilcoyne, A. (2009b). Exenatide compared with long-acting insulin to achieve glycaemic control with minimal weight gain in patients with type 2 diabetes: results of the Helping Evaluate Exenatide in patients with diabetes compared with Long-Acting insulin (HEELA) study. *Diabetes, Obesity and Metabolism*, 11(12), 1153–1162. <https://doi.org/10.1111/j.1463-1326.2009.01154.x>
- Davies, M. J., Leiter, L. A., Guerci, B., Grunberger, G., Ampudia-Blasco, F. J., Yu, C., Stager, W., Niemoeller, E., Souhami, E., & Rosenstock, J. (2017). Impact of baseline HbA1c, diabetes duration and BMI on clinical outcomes in the LixiLan-O trial testing iGlarLixi (insulin glargine/lixisenatide titratable fixed-ratio combination) versus insulin glargine and lixisenatide monocomponents. *Diabetes, Obesity and Metabolism*. <https://doi.org/10.1111/dom.12980>
- Davies, M., Storms, F., Shutler, S., Bianchi-Biscay, M., & Gomis, R. (2005). Improvement of Glycemic Control in Subjects With Poorly Controlled Type 2 Diabetes: Comparison of two treatment algorithms using insulin glargine. *Diabetes Care*, 28(6), 1282–1288. <https://doi.org/10.2337/diacare.28.6.1282>
- Diamant, M., Van Gaal, L., Stranks, S., Northrup, J., Cao, D., Taylor, K., & Trautmann, M. (2010). Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. *The Lancet*, 375(9733), 2234–2243. [https://doi.org/10.1016/S0140-6736\(10\)60406-0](https://doi.org/10.1016/S0140-6736(10)60406-0)
- Evans, M., Schumm-Draeger, P. M., Vora, J., & King, A. B. (2011). A review of modern insulin analogue pharmacokinetic and pharmacodynamic profiles in type 2 diabetes: improvements and limitations. *Diabetes, Obesity and Metabolism*, 13(8), 677–684. <https://doi.org/10.1111/j.1463-1326.2011.01395.x>
- Frandsen, C. S. S., & Madsbad, S. (2014). Efficacy and safety of dipeptidyl peptidase-4 inhibitors as an add-on to insulin treatment in patients with Type 2 diabetes: a review. *Diabetic Medicine*, 31(11), 1293–1300. <https://doi.org/10.1111/dme.12561>
- Funnell, M. M. (2007). Overcoming Barriers to the Initiation of Insulin Therapy. *Clinical Diabetes*, 25(1), 36–38. <https://doi.org/10.2337/diaclin.25.1.36>
- Garber, A. J., Ligthelm, R., Christiansen, J. S., & Liebl, A. (2007). Premixed insulin treatment for type 2 diabetes: analogue or human? *Diabetes, Obesity and Metabolism*, 9(5), 630–639. <https://doi.org/10.1111/j.1463-1326.2006.00654.x>
- Garber, A. J., Wahlen, J., Wahl, T., Bressler, P., Braceras, R., Allen, E., & Jain, R. (2006). Attainment of glycaemic goals in type 2 diabetes with once-, twice-, or thrice-daily dosing

with biphasic insulin aspart 70/30 (The 1-2-3 study). *Diabetes, Obesity and Metabolism*, 8 (1), 58–66. <https://doi.org/10.1111/j.1463-1326.2005.00563.x>

Gough, S. C. L. (2007). A review of human and analogue insulin trials. *Diabetes Research and Clinical Practice*, 77(1), 1–15. <https://doi.org/10.1016/j.diabres.2006.10.015>

Gough, S. C. L., Bhargava, A., Jain, R., Mersebach, H., Rasmussen, S., & Bergenstal, R. M. (2013). Low-Volume Insulin Degludec 200 Units/mL Once Daily Improves Glycemic Control Similarly to Insulin Glargine With a Low Risk of Hypoglycemia in Insulin-Naïve Patients With Type 2 Diabetes. *Diabetes Care*, 36(9), 2536–2542. <https://doi.org/10.2337/dc12-2329>

Gururaj Setty, S., Crasto, W., Jarvis, J., Khunti, K., & Davies, M. J. (2016a). New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal*, 92(1085), 152–164. <https://doi.org/10.1136/postgradmedj-2015-133716>

Gururaj Setty, S., Crasto, W., Jarvis, J., Khunti, K., & Davies, M. J. (2016b). New insulins and newer insulin regimens: a review of their role in improving glycaemic control in patients with diabetes. *Postgraduate Medical Journal*, 92(1085), 152–164. <https://doi.org/10.1136/postgradmedj-2015-133716>

Heller, S. R., Colagiuri, S., Vaaler, S., Wolffenbuttel, B. H. R., Koelendorf, K., Friberg, H. H., Windfeld, K., & Lindholm, A. (2004). Hypoglycaemia with insulin aspart: a double-blind, randomised, crossover trial in subjects with Type 1 diabetes. *Diabetic Medicine*, 21(7), 769–775. <https://doi.org/10.1111/j.1464-5491.2004.01244.x>

Hermansen, K., Davies, M., Derezinski, T., Martinez Ravn, G., Clauson, P., & Home, P. (2006). A 26-Week, Randomized, Parallel, Treat-to-Target Trial Comparing Insulin Detemir With NPH Insulin as Add-On Therapy to Oral Glucose-Lowering Drugs in Insulin-Naive People With Type 2 Diabetes. *Diabetes Care*, 29(6), 1269–1274. <https://doi.org/10.2337/dc05-1365>

Hirsch, I. B., Buse, J. B., Leahy, J., McGill, J. B., Peters, A., Rodbard, H. W., Rubin, R. R., Skyler, J. S., Verderese, C. A., & Riddle, M. C. (2014a). Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. *Diabetes, Obesity and Metabolism*, 16(3), 206–214. <https://doi.org/10.1111/dom.12136>

Hirsch, I. B., Buse, J. B., Leahy, J., McGill, J. B., Peters, A., Rodbard, H. W., Rubin, R. R., Skyler, J. S., Verderese, C. A., & Riddle, M. C. (2014b). Options for prandial glucose management in type 2 diabetes patients using basal insulin: addition of a short-acting GLP-1 analogue versus progression to basal-bolus therapy. *Diabetes, Obesity and Metabolism*, 16(3), 206–214. <https://doi.org/10.1111/dom.12136>

Hirsch, I. B., Franek, E., Mersebach, H., Bardtrum, L., & Hermansen, K. (2017). Safety and efficacy of insulin degludec/insulin aspart with bolus mealtime insulin aspart compared with standard basal-bolus treatment in people with Type 1 diabetes: 1-year results from a randomized clinical trial (BOOST T1). *Diabetic Medicine*, 34(2), 167–173. <https://doi.org/10.1111/dme.13068>

Holman, R. R., Thorne, K. I., Farmer, A. J., Davies, M. J., Keenan, J. F., Paul, S., & Levy, J. C. (2007). Addition of Biphasic, Prandial, or Basal Insulin to Oral Therapy in Type 2 Diabetes.

New England Journal of Medicine, 357(17), 1716–1730.
<https://doi.org/10.1056/NEJMoa075392>

Holman, R. R., & Turner, R. C. (1985). A Practical Guide to Basal and Prandial Insulin Therapy. *Diabetic Medicine*, 2(1), 45–53.
<https://doi.org/10.1111/j.1464-5491.1985.tb00592.x>

Home, P. D. (2012). The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences. *Diabetes, Obesity and Metabolism*, 14(9), 780–788. <https://doi.org/10.1111/j.1463-1326.2012.01580.x>

Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (1996a). Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd. <https://doi.org/10.1002/14651858.CD005613.pub3>

Horvath, K., Jeitler, K., Berghold, A., Ebrahim, S. H., Gratzer, T. W., Plank, J., Kaiser, T., Pieber, T. R., & Siebenhofer, A. (1996b). Long-acting insulin analogues versus NPH insulin (human isophane insulin) for type 2 diabetes mellitus. In *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd. <https://doi.org/10.1002/14651858.CD005613.pub3>

Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2017). Efficacy and safety of glucagon-like peptide-1 receptor agonists in type 2 diabetes: A systematic review and mixed-treatment comparison analysis. *Diabetes, Obesity and Metabolism*. <https://doi.org/10.1111/dom.12849>

Inzucchi, S. E., Bergenstal, R. M., Buse, J. B., Diamant, M., Ferrannini, E., Nauck, M., Peters, A. L., Tsapas, A., Wender, R., & Matthews, D. R. (2015). Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*, 38(1), 140–149. <https://doi.org/10.2337/dc14-2441>

Ismail-Beigi, F. (2012). Glycemic Management of Type 2 Diabetes Mellitus. *New England Journal of Medicine*, 366(14), 1319–1327. <https://doi.org/10.1056/NEJMcp1013127>

June James. (n.d.). Safety and insulin: implementation of national guidance at a local level. *Journal of Diabetes Nursing*.
http://le-primo.hosted.exlibrisgroup.com/primo_library/libweb/action/openurl?ctx=&isServicesPage=true&rft.jtitle=Journal+of+Diabetes+Nursing&rft.aufirst=June∓dscnt=2&url_ctx_fmt=null&vid=44UOLE_services_page&rft.aulast=James&institution=44UOLE&url_ver=Z39.88-2004&rft.atitle=Safety+and+insulin%3A+implementation+of+national+guidance+at+a+local+level&dstmp=1488893669239&fromLogin=true

Khunti, K., Davies, M., Majeed, A., Thorsted, B. L., Wolden, M. L., & Paul, S. K. (2015). Hypoglycemia and Risk of Cardiovascular Disease and All-Cause Mortality in Insulin-Treated People With Type 1 and Type 2 Diabetes: A Cohort Study. *Diabetes Care*, 38(2), 316–322. <https://doi.org/10.2337/dc14-0920>

L. Luzi. (1989). Effect of loss of first-phase insulin secretion on hepatic glucose production and tissue glucose disposal in humans. *American Journal of Physiology - Endocrinology and Metabolism*, 257(2), E241–E246. <http://ajpendo.physiology.org/content/257/2/E241>

Leelarathna, L., Roberts, S. A., Hindle, A., Markakis, K., Alam, T., Chapman, A., Morris, J., Urwin, A., Jinadev, P., & Rutter, M. K. (2017). Comparison of different insulin pump makes under routine care conditions in adults with Type 1 diabetes. *Diabetic Medicine*, 34(10), 1372–1379. <https://doi.org/10.1111/dme.13412>

Luc JC van Loon. (2000). Plasma insulin responses after ingestion of different amino acid or protein mixtures with carbohydrate. *The American Journal of Clinical Nutrition*, 72(1), 96–105. <http://ajcn.nutrition.org/content/72/1/96.full>

MacKinnon, M. (2002). *Providing diabetes care in general practice: a practical guide to integrated care* (4th ed). Class. <https://ebookcentral-proquest-com.ezproxy3.lib.le.ac.uk/lib/leicester/detail.action?docID=581376>

Mäkimmattila, S., Nikkilä, K., & Yki-Järvinen, H. (1999). Causes of weight gain during insulin therapy with and without metformin in patients with Type II diabetes mellitus. *Diabetologia*, 42(4), 406–412. <https://doi.org/10.1007/s001250051172>

Malmberg, K. (1997). Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus. *BMJ*, 314(7093), 1512–1512. <https://doi.org/10.1136/bmj.314.7093.1512>

Marre, M., Shaw, J., Brändle, M., Bebakar, W. M. W., Kamaruddin, N. A., Strand, J., Zdravkovic, M., Le Thi, T. D., & Colagiuri, S. (2009). Liraglutide, a once-daily human GLP-1 analogue, added to a sulphonylurea over 26 weeks produces greater improvements in glycaemic and weight control compared with adding rosiglitazone or placebo in subjects with Type 2 diabetes (LEAD-1 SU). *Diabetic Medicine*, 26(3), 268–278. <https://doi.org/10.1111/j.1464-5491.2009.02666.x>

Marso, S. P., McGuire, D. K., Zinman, B., Poulter, N. R., Emerson, S. S., Pieber, T. R., Pratley, R. E., Haahr, P.-M., Lange, M., Brown-Frandsen, K., Moses, A., Skibsted, S., Kvist, K., & Buse, J. B. (2017). Efficacy and Safety of Degludec versus Glargine in Type 2 Diabetes. *New England Journal of Medicine*. <https://doi.org/10.1056/NEJMoa1615692>

Menting, J. G., Whittaker, J., Margetts, M. B., Whittaker, L. J., Kong, G. K.-W., Smith, B. J., Watson, C. J., Žáková, L., Kletvíková, E., Jiráček, J., Chan, S. J., Steiner, D. F., Dodson, G. G., Brzozowski, A. M., Weiss, M. A., Ward, C. W., & Lawrence, M. C. (2013). How insulin engages its primary binding site on the insulin receptor. *Nature*, 493(7431), 241–245. <https://doi.org/10.1038/nature11781>

Nathan, D. M., Buse, J. B., Davidson, M. B., Heine, R. J., Holman, R. R., Sherwin, R., & Zinman, B. (2006). Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy: A consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. *Diabetes Care*, 29(8), 1963–1972. <https://doi.org/10.2337/dc06-9912>

Nauck, M. (2016). Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors. *Diabetes, Obesity and Metabolism*, 18(3), 203–216. <https://doi.org/10.1111/dom.12591>

New IDegLira data show rapid and predictable glycaemic improvements in people with

type 2 diabetes. (n.d.).

<http://www.multivu.com/players/English/72762519-novo-nordisk-IDegLira-treatment/>

Pickup, J. C., Reznik, Y., & Sutton, A. J. (2017). Glycemic Control During Continuous Subcutaneous Insulin Infusion Versus Multiple Daily Insulin Injections in Type 2 Diabetes: Individual Patient Data Meta-analysis and Meta-regression of Randomized Controlled Trials. *Diabetes Care*, 40(5), 715–722. <https://doi.org/10.2337/dc16-2201>

Professor Kamlesh Khunti - Coding, Classification and Diagnosis of Diabetes. (4 C.E.). <https://www.youtube.com/watch?v=AhhWTmEFuag>

Raccach, D., Huet, D., Dib, A., Joseph, F., Landers, B., Escalada, J., & Schmitt, H. (2017a). Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. *Diabetic Medicine*. <https://doi.org/10.1111/dme.13390>

Raccach, D., Huet, D., Dib, A., Joseph, F., Landers, B., Escalada, J., & Schmitt, H. (2017b). Review of basal-plus insulin regimen options for simpler insulin intensification in people with Type 2 diabetes mellitus. *Diabetic Medicine*, 34(9), 1193–1204. <https://doi.org/10.1111/dme.13390>

Raskin, P., Allen, E., Hollander, P., Lewin, A., Gabbay, R. A., Hu, P., Bode, B., & Garber, A. (2005). Initiating Insulin Therapy in Type 2 Diabetes: A comparison of biphasic and basal insulin analogs. *Diabetes Care*, 28(2), 260–265. <https://doi.org/10.2337/diacare.28.2.260>

Reduced weight gain with insulin detemir compared to NPH insulin is not explained by a reduction in hypoglycemia. - PubMed - NCBI. (n.d.). <http://www.ncbi.nlm.nih.gov/pubmed/18715200>

Richard I. G. Holt, , Clive Cockram, , Allan Flyvbjerg, , and Barry J. Goldstein. (2016). *Textbook of Diabetes*. John Wiley & Sons, Incorporated. <https://ebookcentral-proquest-com.ezproxy3.lib.le.ac.uk/lib/leicester/reader.action?docID=4769056&query=#>

Richter, B., & Neises, G. (1996). 'Human' insulin versus animal insulin in people with diabetes mellitus. In *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd. <https://doi.org/10.1002/14651858.CD003816.pub2>

Riddle, M. C., Aronson, R., Home, P., Marre, M., Niemoeller, E., Miossec, P., Ping, L., Ye, J., & Rosenstock, J. (2013). Adding Once-Daily Lixisenatide for Type 2 Diabetes Inadequately Controlled by Established Basal Insulin. *Diabetes Care*, 36(9), 2489–2496. <https://doi.org/10.2337/dc12-2454>

Rodbard, H. W., Bode, B. W., Harris, S. B., Rose, L., Lehmann, L., Jarlov, H., & Thurman, J. (2017). Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial. *Diabetic Medicine*, 34(2), 189–196. <https://doi.org/10.1111/dme.13256>

Rorsman, P., & Renström, E. (2003). Insulin granule dynamics in pancreatic beta cells. *Diabetologia*, 46(8), 1029–1045. <https://doi.org/10.1007/s00125-003-1153-1>

Rosenstock, J., Davies, M., Home, P. D., Larsen, J., Koenen, C., & Schernthaner, G. (2008). A

randomised, 52-week, treat-to-target trial comparing insulin detemir with insulin glargine when administered as add-on to glucose-lowering drugs in insulin-naive people with type 2 diabetes. *Diabetologia*, 51(3), 408–416. <https://doi.org/10.1007/s00125-007-0911-x>

Rosenstock, J., Jelaska, A., Frappin, G., Salsali, A., Kim, G., Woerle, H. J., & Broedl, U. C. (2014). Improved Glucose Control With Weight Loss, Lower Insulin Doses, and No Increased Hypoglycemia With Empagliflozin Added to Titrated Multiple Daily Injections of Insulin in Obese Inadequately Controlled Type 2 Diabetes. *Diabetes Care*, 37(7), 1815–1823. <https://doi.org/10.2337/dc13-3055>

Rosenstock, J., Raccach, D., Koranyi, L., Maffei, L., Boka, G., Miossec, P., & Gerich, J. E. (2013). Efficacy and Safety of Lixisenatide Once Daily Versus Exenatide Twice Daily in Type 2 Diabetes Inadequately Controlled on Metformin: A 24-week, randomized, open-label, active-controlled study (GetGoal-X). *Diabetes Care*, 36(10), 2945–2951. <https://doi.org/10.2337/dc12-2709>

Sharon Allard, Caroline Butler, Sue Cradock, Heather Daly, Jemma Edwards, Elizabeth Gilbert. (2010). Using Conversation Maps in practice: the UK experience. *Journal of Diabetes Nursing*, 14(1).

<http://go.galegroup.com/ps/i.do?id=GALE|A245106172&v=2.1&u=leicester&it=r&p=EAIM&sw=w&asid=fe5329820c5da4ed2dd0a88a5ced5962>

Srinivasan, B. T., & Davies, M. (2014). Glycaemic management of type 2 diabetes. *Medicine*, 42(12), 711–717. <https://doi.org/10.1016/j.mpmed.2014.09.011>

Srinivasan, B. T., Jarvis, J., Khunti, K., & Davies, M. J. (2008). Recent advances in the management of type 2 diabetes mellitus: a review. *Postgraduate Medical Journal*, 84(996), 524–531. <https://doi.org/10.1136/pgmj.2008.067918>

Swinnen, S. G., Simon, A. C., Holleman, F., Hoekstra, J. B., & DeVries, J. H. (1996). Insulin detemir versus insulin glargine for type 2 diabetes mellitus. In *Cochrane Database of Systematic Reviews*. John Wiley & Sons, Ltd.

<https://doi.org/10.1002/14651858.CD006383.pub2>

Villani, M., de Courten, B., & Zoungas, S. (2017). Emergency treatment of hypoglycaemia: a guideline and evidence review. *Diabetic Medicine*, 34(9), 1205–1211. <https://doi.org/10.1111/dme.13379>

Wahren, J., & Kallas, A. (2012). Loss of Pulsatile Insulin Secretion: A Factor in the Pathogenesis of Type 2 Diabetes? *Diabetes*, 61(9), 2228–2229. <https://doi.org/10.2337/db12-0664>

Walker, R. A., Rodgers, J., & Diabetes UK. (2010). *Diabetes: a practical guide to managing your health* (Fully revised and updated). Dorling Kindersley.

Wang, W., Liu, H., Xiao, S., Liu, S., Li, X., & Yu, P. (2017). Effects of Insulin Plus Glucagon-Like Peptide-1 Receptor Agonists (GLP-1RAs) in Treating Type 1 Diabetes Mellitus: A Systematic Review and Meta-Analysis. *Diabetes Therapy*.

<https://doi.org/10.1007/s13300-017-0282-3>

Yki-Järvinen, H., Kauppinen-Mäkelin, R., Tiikkainen, M., Vähätalo, M., Virtamo, H., Nikkilä, K., Tulokas, T., Hulme, S., Hardy, K., McNulty, S., Hänninen, J., Levänen, H., Lahdenperä, S.,

Lehtonen, R., & Ryysy, L. (2006). Insulin glargine or NPH combined with metformin in type 2 diabetes: the LANMET study. *Diabetologia*, 49(3), 442–451.

<https://doi.org/10.1007/s00125-005-0132-0>

Young, L. A., & Buse, J. B. (2014). GLP-1 receptor agonists and basal insulin in type 2 diabetes. *The Lancet*, 384(9961), 2180–2181.

[https://doi.org/10.1016/S0140-6736\(14\)61409-4](https://doi.org/10.1016/S0140-6736(14)61409-4)

Zinman, B., Fulcher, G., Rao, P. V., Thomas, N., Endahl, L. A., Johansen, T., Lindh, R., Lewin, A., Rosenstock, J., Pinget, M., & Mathieu, C. (2011). Insulin degludec, an ultra-long-acting basal insulin, once a day or three times a week versus insulin glargine once a day in patients with type 2 diabetes: a 16-week, randomised, open-label, phase 2 trial. *The Lancet*, 377(9769), 924–931. [https://doi.org/10.1016/S0140-6736\(10\)62305-7](https://doi.org/10.1016/S0140-6736(10)62305-7)